H.R.467 — HALT Fentanyl Act
House Roll Call
H.R.467
| Bill | H.R.467 — HALT Fentanyl Act |
|---|---|
| Vote question | On Passage |
| Vote type | Yea-and-Nay |
| Result | Passed |
| Totals | Yea 289 / Nay 133 / Present 0 / Not Voting 13 |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| R | 215 | 1 | 0 | 6 |
| D | 74 | 132 | 0 | 7 |
| I | 0 | 0 | 0 | 0 |
Research Brief
On Passage
Bill Analysis
The HALT Fentanyl Act (HR 467) aims to address the escalating crisis of fentanyl-related overdoses and trafficking in the United States. The bill proposes to permanently classify fentanyl-related substances as Schedule I drugs under the Controlled Substances Act, which would impose stricter regulations on their manufacture, distribution, and possession. This classification is intended to enhance law enforcement capabilities in combating the proliferation of these dangerous substances.
The bill authorizes the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) to take more aggressive actions against the trafficking of fentanyl and its analogs. It also mandates that the DOJ and DEA collaborate with state and local law enforcement agencies to improve intelligence sharing and operational coordination in drug enforcement efforts.
Funding for the initiatives outlined in the HALT Fentanyl Act is expected to come from existing federal resources allocated for drug enforcement and public health initiatives. The bill emphasizes the importance of supporting programs that provide treatment and recovery services for individuals affected by opioid addiction, thereby benefiting both law enforcement and public health entities.
Key beneficiaries of the HALT Fentanyl Act include local communities facing the opioid crisis, healthcare providers engaged in addiction treatment, and law enforcement agencies tasked with drug enforcement. The bill aims to protect public health and safety by reducing the availability of fentanyl and its analogs, which are linked to a significant increase in overdose deaths.
The legislative timeline indicates that the bill has been received in the Senate, where it has been read twice and referred to the Committee on the Judiciary for further consideration. The progression of the bill will depend on committee discussions and potential amendments before it can be brought to the Senate floor for a vote.
Yea (289)
K
Kelly Armstrong
D
Dan Bishop
K
Ken Buck
L
Larry Bucshon
M
Michael Burgess
K
Ken Calvert
Y
Yadira Caraveo
J
Jerry Carl
M
Matt Cartwright
L
Lori Chavez-DeRemer
A
Anthony D'Esposito
J
John Duarte
J
Jeff Duncan
A
A. Ferguson
S
Scott Franklin
M
Matt Gaetz
M
Mike Gallagher
R
Ruben Gallego
J
John Garamendi
M
Mike Garcia
B
Bob Good
K
Kay Granger
G
Garret Graves
M
Mark Green
B
Brian Higgins
J
Jeff Jackson
B
Bill Johnson
D
Daniel Kildee
D
Derek Kilmer
D
Doug Lamborn
J
Jake LaTurner
D
Debbie Lesko
B
Blaine Luetkemeyer
K
Kathy Manning
K
Kevin McCarthy
L
Lisa McClain
P
Patrick McHenry
M
Marcus Molinaro
W
Wiley Nickel
M
Mary Peltola
G
Greg Pence
D
Dean Phillips
B
Bill Posey
C
Cathy Rodgers
M
Matthew Rosendale
C
C. Ruppersberger
J
John Rutherford
G
George Santos
D
David Schweikert
P
Pete Sessions
A
Abigail Spanberger
M
Michelle Steel
C
Chris Stewart
M
Michael Waltz
B
Brad Wenstrup
J
Jennifer Wexton
S
Susan Wild
B
Brandon Williams
Nay (133)
C
Colin Allred
E
Earl Blumenauer
J
Jamaal Bowman
C
Cori Bush
T
Tony Cárdenas
G
Gerald Connolly
J
Jason Crow
L
Lloyd Doggett
A
Anna Eshoo
R
Raúl Grijalva
A
Ann Kuster
B
Barbara Lee
L
Lucy McBath
B
Bill Pascrell
D
Donald Payne
K
Katie Porter
J
John Sarbanes
E
Eric Swalwell
R
Rashida Tlaib
D
David Trone
N
Nydia Velázquez
D
Debbie Wasserman Schultz
Not Voting (13)
D
David Cicilline
S
Sheila Jackson Lee
A
Alexander Mooney
G
Grace Napolitano
